Art of Medicine to the Sciences of Health

submitted by: Phil

Lecture by Howard Asher to the UCSD Pharmacy Informatics (SPPS205) class. The lecture covers the problems and promise of health care with an emphasis on informatics issues, particularly as it related to pharmacists.

Video tip of the week: Highlights [heh] of the Cannabis browser

submitted by: OpenHelix

An introduction to the Cannabis genome browser. For the paper and links, visit .

Diabetes Drugs Market And Diabetes Devices Market 2011 to 2016

submitted by: tmrreport

The Global Market for Diabetes Management accounted for USD 40 billion in 2010 and is expected to attain a market size of around USD 114 billion following a growth rate of 13.5% CAGR.

Counterfeit Avastin - Not At MD Anderson

submitted by: mdanderson Last week, the maker of the widely used cancer drug Avastin, issued a warning that a counterfeit version of the drug was discovered in the United States. The announcement revived concerns among hospital officials, government regulators, doctors and patients about the growing threat of fake drugs. Read the full story on Cancerwise Upon learning of the notice, MD Anderson pharmacy staff examined their supply of Avastin and confirmed that none of...

Preparing the Next Generation of Clinical Pharmacists

submitted by: mdanderson
Most undergraduate pharmacy education involves didactic learning, with little patient contact until late in the process, says Joel LaJeunesse, vice president for the Division of Pharmacy. But, at MD Anderson, pharmacy residents get plenty of direct patient contact through the Pharmacy Graduate Year 2 (PGY2) program. PGY2 allows those who've completed a one-year residency in pharmacy to specialize in one of two areas for another year. Six residents specialize in oncology; two focus on...

Patient Discusses Clinical Trial For Advanced Breast Cancer

submitted by: mdanderson
Seven years ago, Suzanne Hebert was diagnosed with metastatic breast cancer that spread to her liver and bones. After four rounds of chemotherapy and decreasing response rates, she decided it was time for a change. That change came after advice from a friend, who also had advanced breast cancer, and was enrolled on a clinical trial at MD Anderson. The trial combined two drugs, everolimus, and a hormone therapy called arimidex. A different trial named BOLERO-2, or Breast Cancer Trials of...